News|Articles|May 31, 2016

FDA Releases Guidance on Topical Patches

The agency publishes draft guidance on assessing the adhesion of transdermal delivery systems and topical patches.

On May 31, 2016, FDA issued draft guidance on recommendations for designing and performing studies to evaluate adhesive performance in transdermal delivery systems or topical patches submitted with an abbreviated new drug application (ANDA). The draft guidance addresses the agency’s thinking in regards to adhesion scoring systems; adhesion studies including study design, study conduct, and statistical analysis; adhesion and bioequivalence; and formatting data submission.

FDA states that the new draft guidance supersedes “recommendations related to adhesion studies provided in individual product-specific guidances published prior to the date of publication of this guidance.”

Source: FDA


Related to this article

PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.